Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1995 2
1996 17
1997 3
1998 3
2000 2
2001 1
2002 6
2003 4
2004 3
2005 12
2006 9
2007 14
2008 8
2009 15
2010 13
2011 9
2012 5
2013 9
2014 4
2015 2
2016 4
2017 2
2018 2
2019 2
2020 5
2021 6
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
D-mannose for preventing and treating urinary tract infections.
Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. Cooper TE, et al. Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD013608. doi: 10.1002/14651858.CD013608.pub2. Cochrane Database Syst Rev. 2022. PMID: 36041061 Free PMC article. Review.
D-mannose 500 mg plus supplements (N-acetylcysteine and Morinda citrifolia fruit extract) had uncertain effects on symptomatic and bacteriuria-confirmed UTIs when compared to an antibiotic (prulifloxacin 400 mg) (1 study, 75 participants; very low certainty evidence). ...
D-mannose 500 mg plus supplements (N-acetylcysteine and Morinda citrifolia fruit extract) had uncertain effects on symptomatic and bacteriur …
Prulifloxacin.
Keam SJ, Perry CM. Keam SJ, et al. Drugs. 2004;64(19):2221-34; discussion 2235-6. doi: 10.2165/00003495-200464190-00005. Drugs. 2004. PMID: 15456336 Clinical Trial.
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. ...Prulifloxacin was generally well tolerated in clinical trials, with a similar tolerability profile to that of ciprofloxacin....
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. ...Prulifloxacin was …
Role of prulifloxacin in the treatment of acute rhinosinusitis.
Passali D, Crisanti A, Bellussi LM. Passali D, et al. Infez Med. 2015 Dec;23(4):301-6. Infez Med. 2015. PMID: 26700078 Free article. Review.
Ulifloxacin T(1/2) and plasma and tissue concentrations including the nose-paranasal sinuses mucosa allow once daily administration at the dosage of 600 mg. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for …
Ulifloxacin T(1/2) and plasma and tissue concentrations including the nose-paranasal sinuses mucosa allow once daily administration at the d …
Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G, Rossi V, Salvatori E, Mirelis B. Prats G, et al. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. doi: 10.1586/14787210.4.1.27. Expert Rev Anti Infect Ther. 2006. PMID: 16441207 Review.
Prulifloxacin is available for oral use, and after absorption is metabolized in to the active form, ulifloxacin. ...This review focuses on the characteristics of prulifloxacin, summarizing the relevant preclinical and clinical data....
Prulifloxacin is available for oral use, and after absorption is metabolized in to the active form, ulifloxacin. ...This review focus …
Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
Giannarini G, Tascini C, Selli C. Giannarini G, et al. Future Microbiol. 2009 Feb;4(1):13-24. doi: 10.2217/17460913.4.1.13. Future Microbiol. 2009. PMID: 19207096 Review.
Prulifloxacin, the lipophilic prodrug of ulifloxacin, is a new oral fluoroquinolone with a broad spectrum of in vitro activity against various Gram-positive and Gram-negative microorganisms. ...Results are awaited from recently completed and ongoing Phase III randomized, p …
Prulifloxacin, the lipophilic prodrug of ulifloxacin, is a new oral fluoroquinolone with a broad spectrum of in vitro activity agains …
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y, Ozaki M, Matsuda M, Honmura T, Nishimura I, Yamaguchi R, Adachi T, Okawa Y, Nishino T. Tomii Y, et al. Arzneimittelforschung. 1996 Dec;46(12):1169-73. Arzneimittelforschung. 1996. PMID: 9006794
Against urinary tract infection with olfloxacin-resistant Enterobacter cloacae, prulifloxacin was the most effective of all the drugs tested. 3. The maximal serum concentration of prulifloxacin was slightly higher than that of ciprofloxacin, and the area under the c …
Against urinary tract infection with olfloxacin-resistant Enterobacter cloacae, prulifloxacin was the most effective of all the drugs …
Pharmacologic characteristics of prulifloxacin.
Matera MG. Matera MG. Pulm Pharmacol Ther. 2006;19 Suppl 1:20-9. doi: 10.1016/j.pupt.2005.09.009. Epub 2005 Dec 19. Pulm Pharmacol Ther. 2006. PMID: 16360331 Review.
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption, prulifloxacin is metabolized by esterases to ulifloxacin. The drug has a long elimination half-life, allowing once-daily administration. ...
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption, prulifl …
Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME. Rafailidis PI, et al. Int J Antimicrob Agents. 2011 Apr;37(4):283-90. doi: 10.1016/j.ijantimicag.2010.11.032. Int J Antimicrob Agents. 2011. PMID: 21300527 Review.
Regarding traveller's diarrhoea, prulifloxacin resulted in better clinical and microbiological outcomes compared with placebo. ...In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea....
Regarding traveller's diarrhoea, prulifloxacin resulted in better clinical and microbiological outcomes compared with placebo. ...In …
Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis.
Cazzola M, Salvatori E, Dionisio P, Allegra L. Cazzola M, et al. Pulm Pharmacol Ther. 2006;19 Suppl 1:30-7. doi: 10.1016/j.pupt.2005.09.007. Epub 2005 Dec 15. Pulm Pharmacol Ther. 2006. PMID: 16359895 Review.
Statistical analyses indicated a significant linear trend between the prulifloxacin 300, 450, and 600 mg doses, which would point to an interesting relationship between dose employed and response obtained. ...In particular, since good patient compliance is a key factor in …
Statistical analyses indicated a significant linear trend between the prulifloxacin 300, 450, and 600 mg doses, which would point to …
Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics.
Giusti M, Blasi F, Iori I, Mazzone A, Sgambato F, Politi C, Colagrande P, Casali A, Valerio A, Gussoni G, Bonizzoni E, Campanini M. Giusti M, et al. COPD. 2016 Oct;13(5):555-60. doi: 10.3109/15412555.2016.1152236. Epub 2016 Mar 30. COPD. 2016. PMID: 27027547 Clinical Trial.
The FADOI-FLOR study is a randomized, single-blind, non-inferiority comparison between levofloxacin and prulifloxacin. Primary end-point was "therapeutic success" at Day 10 of treatment, defined as disappearance of signs/symptoms or decrease of at least three points of a g …
The FADOI-FLOR study is a randomized, single-blind, non-inferiority comparison between levofloxacin and prulifloxacin. Primary end-po …
161 results